Cailin Conner

DocwireNews

A retrospective cohort study conducted at a U.S. tertiary center between 2018 and 2021 sought to assess the association between continuous glucose monitoring (CGM) metrics and perinatal outcomes to identify optimal targets for mitigating morbidity. The study was published in <a href="https://diabetesjournals.org/care/article-abstract/doi/10.2337/dc23-0636/153675/Association-of-Continuous-Glucose-Monitoring?redirectedFrom=fulltext" target="_blank" rel="noopener">Diabetes Care</a>.The study focused on pregnant patients with type 1 or type 2 diabetes who used real-time CGM and delivered at the designated center. The cohort excluded cases of multiple gestations, fetal anomalies, and early pregnancy loss. Various CGM metrics were assessed, including time in range (TIR; 65-140 mg/dL), time above range, time below range (TBR), glucose variability, average glucose, and the glucose management indicator.The primary outcome comprised a composite of fetal or neonatal mortality, infants classified as large or small for gestational age at birth, neonatal intensive care unit admissions, instances of hypoglycemia, shoulder dystocia or birth trauma, and hyperbilirubinemia. Logistic regression was employed to evaluate the association between CGM metrics and these outcomes, leading to the determination of optimal TIR.The study cohort consisted of 117 patients, of whom 16 (13.7%) had been using CGM before pregnancy, and 68 (58.1%) had type 1 diabetes. Overall, 83.8% of the patients experienced the composite neonatal outcome, emphasizing the significance of achieving optimal glucose control during pregnancy.All CGM metrics, with the exception of TBR, exhibited associations with neonatal morbidity. Specifically, for every 5 percentage-point increase in TIR, the odds of neonatal morbidity decreased by 28% (odds ratio, 0.72; 95% CI, 0.58-0.89). This led to the identification of an optimal TIR range, specifically between 66% and 71%.The investigators concluded, &ldquo;Nearly all CGM metrics were associated with adverse neonatal morbidity and mortality and may aid management of preexisting diabetes in pregnancy. Our findings support the American Diabetes Association recommendation of 70% TIR.&rdquo;

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

HER2 Breast Cancer

Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1+ mTNBC, Phase III Data Show

Triple-Negative Breast Cancer

Latest News

Evidence-Based CGM Targets to Improve Maternal and Neonatal Health in Diabetic Pregnancies

Diabetes

Study findings supported the recommendation of a 70% time in range for pregnant patients with type 1 or type 2 diabetes using CGM to optimize maternal and neonatal health.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe